氟托西匹-PET与血浆p-Tau217同阿尔茨海默病及其他神经退行性疾病中tau神经病理的关联
该回顾性尸检队列研究纳入73例临床神经退行性疾病患者,评估氟托西匹-PET和血浆p-tau217与AD神经病理改变(ADNC)的关联,发现两者对Braak V-VI期识别性能高,PET在识别高/中间ADNC上优于血浆p-tau217。
要点
- 氟托西匹-PET和血浆p-tau217对Braak V-VI期识别AUC分别为0.92和0.90。
- PET识别高/中间ADNC的AUC为0.94,优于血浆p-tau217的0.89。
- 两标志物对原发AD神经病理诊断特异性强,对非AD早期tau共病理敏感性有限。
核心结论
- 氟托西匹-PET和血浆p-tau217对原发AD神经病理诊断均显示强特异性,但对非AD诊断中早期tau共病理敏感性有限。
研究设计与样本
- 加州大学旧金山分校神经退行性疾病脑库2013至2024年回顾性研究,纳入73例临床神经退行性疾病且生前接受氟托西匹-PET和尸检的参与者。
主要发现
- AD神经病理诊断者氟托西匹SUVR高于非AD参与者,NFT Braak VI期和高ADNC水平在内嗅皮层和颞叶meta-ROI均见持续升高的PET信号。
- 中间ADNC水平未见PET信号升高。
- AD NFT负荷与局部氟托西匹SUVR及血浆p-tau217浓度跨皮层脑区相关。
- 血浆p-tau217在Braak V和VI期升高,与氟托西匹SUVR相关(r≥0.75)。
- 两标志物识别Braak V-VI期性能相似:内嗅SUVR AUC=0.92(95%CI 0.91-0.93),颞叶meta-ROI SUVR AUC=0.91(95%CI 0.90-0.92),血浆p-tau217 AUC=0.90(95%CI 0.89-0.91)。
关键数值与推荐
- 氟托西匹-PET在注射后80-100分钟采集,以内嗅皮层和小脑下皮层归一化提取SUVR。
- 血浆p-tau217采用Simoa(Janssen)定量,56例参与者中位PET至血浆间隔1.6个月(IQR 0.24-3.7)。
- 56例参与者有皮层AD NFT负荷半定量评级。
- 诊断性能采用交叉验证的受试者工作特征分析评估。
临床怎么用
- 氟托西匹-PET和血浆p-tau217可用于识别晚期Braak V-VI期tau病理,PET对高/中间ADNC识别更优。
- 在非AD神经退行性疾病中,两标志物对早期tau共病理敏感性有限,解读阴性结果需谨慎。
局限性
- 回顾性单中心脑库研究,样本量73例,部分分析仅56例。
- PET至尸检中位间隔3.9年(IQR 2.1-5.1),存在时间间隔影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Evaluating tau biomarkers in patients with autopsy data is critical for validating their sensitivity and specificity to Alzheimer disease (AD) neuropathologic changes (ADNCs). We examined associations between [18F]flortaucipir tau PET, plasma phosphorylated-tau 217 (p-tau217), and AD neuropathology in a cohort of clinically impaired participants from a tertiary dementia center. METHODS: This was a retrospective study conducted at the University of California San Francisco Neurodegenerative Disease Brain Bank that included all participants with a clinical diagnosis of neurodegenerative disease who underwent antemortem flortaucipir-PET and autopsy from 2013 to 2024. Flortaucipir-PET was acquired 80-100 minutes after injection and normalized to the inferior cerebellar cortex; standardized uptake value ratios (SUVRs) were extracted from the entorhinal cortex (early tau region) and the temporal meta-regions of interest (ROIs) (AD-signature region). Plasma p-tau217 was quantified using Simoa (Janssen) in 56 participants (median [interquartile range, IQR] PET-to-plasma duration: 1.6 months [0.24-3.7]). Semiquantitative rating of AD neurofibrillary tangle (NFT) burden in cortical areas was available for 56 participants. The diagnostic performance of tau PET and plasma p-tau217 was assessed using receiver operating characteristic analysis with cross-validation. RESULTS: We analyzed 73 participants (median [IQR] age: 67 [59-73] years, 60% male, median [IQR] PET-to-autopsy duration: 3.9 [2.1-5.1] years) with primary neuropathologic diagnosis of AD (n = 39), frontotemporal lobar degeneration (tauopathies, n = 26; nontauopathies, n = 4), chronic traumatic encephalopathy (n = 2), and Lewy body disease (n = 2). Flortaucipir SUVRs were elevated in participants with a neuropathologic diagnosis of AD compared with non-AD participants. Consistently elevated PET signal was detected in both the entorhinal cortex and temporal meta-ROIs at NFT Braak stage VI and high ADNC levels. No PET signal elevation was observed at intermediate ADNC levels. AD NFT burden correlated with local flortaucipir SUVRs and plasma p-tau217 concentrations across cortical brain regions. Plasma p-tau217 concentrations increased at Braak stages V and VI and correlated with flortaucipir SUVRs (r's ≥ 0.75). Both markers identified Braak stage V-VI levels with similarly high performance (entorhinal SUVR, area under the curve [AUC] = 0.92 [95% CI 0.91-0.93]; temporal meta-ROI SUVR, AUC = 0.91 [95% CI 0.90-0.92]; plasma p-tau217, AUC = 0.90 [95% CI 0.89-0.91]), but PET outperformed plasma p-tau217 in identifying high/intermediate ADNCs (entorhinal ROI, AUC = 0.94 [95% CI 0.94-0.95]; temporal meta-ROI AUC = 0.94 [95% CI 0.94-0.95]; plasma p-tau217, AUC = 0.89 [95% CI 0.88-0.90]). DISCUSSION: Flortaucipir-PET and plasma p-tau217 both displayed strong specificity for primary AD neuropathologic diagnosis but limited sensitivity for early tau co-pathology in non-AD diagnoses.
引用
- Vrillon A, Spina S, Mejía-Pérez J, et al. Association of [18F]Flortaucipir-PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders. Neurology. 2026. PMID: 41628396. doi:10.1212/WNL.0000000000214576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。